Biotinylated Human DDR1 Protein, His,Avitag™ (MALS verified)
分子别名（Synonym）
CD167a
表达区间及表达系统（Source）
Biotinylated Human DDR1, His,Avitag (DD1-H82E9) is expressed from human 293 cells (HEK293). It contains AA Asp 21 - Thr 416 (Accession # Q08345-1).
Predicted N-terminus: Asp 21
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 47.5 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记（Biotinylation）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Biotin:Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
Discoidin结构域受体1（DDR1）是DDR的成员，DDR是受体酪氨酸激酶（RTK）的成员。在胶原结合后，DDR1经历酪氨酸自磷酸化，从而触发下游遗传和细胞途径，并在细胞形态发生、分化、增殖、粘附、迁移和侵袭的调节中发挥关键作用。研究表明，DDR1与多种人类疾病密切相关，包括癌症、纤维化、动脉粥样硬化和其他炎症性疾病。新一代DDR1抑制剂靶向规范ATP结合袋或细胞外结构域外的变构位点（变构抑制剂），可能为选择性DDR1抑制疗法的开发提供新的机会。
关键字： DDR1;DDR1蛋白;DDR1重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。